The application of liposomal azelaic acid, 4-n butyl resorcinol and retinol serum enhanced by microneedling for treatment of malar pattern melasma: A case series


Published: 29 March 2019
Abstract Views: 2923
PDF: 652
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Arie Kusumawardani Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi General Hospital of Surakarta, Indonesia.
  • Anggana Rafika Paramitasari Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi general hospital of Surakarta, Indonesia.
  • Susanti Rosmala Dewi Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi general hospital of Surakarta, Indonesia.
  • Ance Imelda Betaubun Dermatovenereology Department Faculty of Medicine Sebelas Maret University dr. Moewardi general hospital of Surakarta, Indonesia.

Melasma is a common hypermelanosis disorder that can be frustrating both for patients and physicians because it is very difficult to treat. Azelaic acid, 4-n-butylresorcinol and retinol is some of treatment modalities for melasma, but until now there is no clinical trial studies about combination of these three agents. We reported three mixed type melasma patients whom we treated using liposomal serum containing azelaic acid, 4-n-butylresorcinol and retinol combined with microneedling. We measured the improvement with modified Melasma Severity Index (MASI), Melasma Severity Scale (MSS) and Melas-QoL quesionner. At the start of the trial the average MASI score of all patients was 5.9, MSS was moderate and Melas QoL was 55.3. We re-applied treatment every 14 days for four times. There were improvements in their MASI with the ranged of 41.7%-85%, and Melas-QoL 38.8-83.3%. All of MSS in these three patients was classified into mild in the end of therapy.


Kusumawardani, A., Paramitasari, A. R., Dewi, S. R., & Betaubun, A. I. (2019). The application of liposomal azelaic acid, 4-n butyl resorcinol and retinol serum enhanced by microneedling for treatment of malar pattern melasma: A case series. Dermatology Reports, 11(s1). https://doi.org/10.4081/dr.2019.8075

Downloads

Download data is not yet available.

Citations